How did RU58841 come about?
The concept of RU58841 is quite old. The idea to develop it was first put forth by a French pharmaceutical company called Roussel Uclaf, way back in the 1970s. Although it had been produced in the 80s, most of the research about its development progressed into the 90s.
The main aim of these scientists was to develop a potent medication that would effectively manage acne and androgenic alopecia when applied topically while avoiding/limiting systemic side effects that are commonly observed with other anti-androgens.
Rats and hamsters were the animal models used to test its effectiveness. During the trial phase of the mediation, the RU58841 results were very promising.
Actually, even small doses as low as 0.001 milligrams showed significant local effects. Even at high doses of up to 0.01 milligrams, the action was still limited to the site of application – a much-desired relief for the researchers.
A lot has transpired since the inception of the idea. For instance, several companies had acquired and dropped their right to this product. Eventually, one company – ProStraken – acquired the full rights to RU58841 and changed its name to PSK3841.
Phendimetrazine is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is used by certain overweight people, such as those who are obese or have weight-related medical problems.
Losing weight and keeping it off can lessen the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life.It is not known how this medication helps people to lose weight. It may work by decreasing your appetite, increasing the amount of energy used by your body, or by affecting certain parts of the brain.
This medication is an appetite suppressant and belongs to a class of drugs called sympathomimetic amines.